LABU240906C148000
- 2.20
- -2.65-54.64%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $295
Alnylam Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
United Therapeutics Is Maintained at Outperform by Oppenheimer
United Therapeutics Analyst Ratings
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $575
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Exact Sciences Analyst Ratings
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Alnylam Pharmaceuticals Price Target Raised to $280.00/Share From $248.00 by JP Morgan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
Regeneron Pharmaceuticals Analyst Ratings
AbbVie Analyst Ratings
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242